-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Management of Aggressive Lymphoma After CAR T-Cell Therapy Failure

Program: Education Program
Session: How Do We Calibrate Cellular Therapy for Lymphoma in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Lymphomas, non-Hodgkin lymphoma, Bispecific Antibody Therapy, Non-Biological therapies, Clinical Research, health outcomes research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Combination therapy, Checkpoint Inhibitor, drug development, Diseases, indolent lymphoma, real-world evidence, aggressive lymphoma, Therapies, Immunotherapy, Lymphoid Malignancies, Monoclonal Antibody Therapy, Natural Killer (NK) Cell Therapies
Saturday, December 9, 2023, 9:30 AM-10:45 AM

Loretta J. Nastoupil, MD

Lymphoma/Myeloma Department, MD Anderson Cancer Center, Houston, TX; Department of Lymphoma and Myeloma, UT MD Anderson Cancer Center, Houston, TX

Disclosures: Nastoupil: Gilead Sciences/Kite Pharma: Honoraria, Research Funding; AstraZeneca: Honoraria; Genentech, Inc., Genmab, Gilead/Kite, Janssen, Merck, Novartis, Takeda: Honoraria, Research Funding; Regeneron: Honoraria; Daiichi Sankyo: Honoraria, Research Funding; DeNovo: Honoraria; Caribou Biosciences: Honoraria, Research Funding; Bristol Myers Squibb/Celgene: Honoraria, Research Funding; ADC Therapeutics: Honoraria; AbbVie: Honoraria.